Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-tRNA synthetases
Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
1. A therapeutic composition, comprising an isolated aspartyl-tRNA synthetase (DRS) polypeptide of up to about 280 amino acids in length that comprises SEQ ID NO:16 or an amino acid sequence that is at least 95% identical to SEQ ID NO:16, wherein the polypeptide has an extracellular signaling activity and a solubility of at least about 5 mg/mL, and wherein the composition has a purity of at least about 95% on a protein basis and less than about 10 EU endotoxin/mg protein.
2. The therapeutic composition of claim 1 , wherein the DRS polypeptide specifically binds to a binding partner to exert a physiological effect.
3. The therapeutic composition of claim 1 , wherein the DRS polypeptide consists of SEQ ID NO:16 or differs from SEQ ID NO:16 by substitution, deletion, and/or addition of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acids, and wherein the altered polypeptide retains an extracellular signaling activity of the unaltered polypeptide.
4. The therapeutic composition of claim 1 , wherein the DRS polypeptide is fused to a heterologous polypeptide.
5. The therapeutic composition of claim 1 , wherein at least one moiety or a solid substrate is covalently or non-covalently attached to said polypeptide.
6. The therapeutic composition of claim 1 , wherein the AARS polypeptide is fused to a pharmacokinetic (PK) property modifier.
7. The therapeutic composition of claim 3 , wherein the DRS polypeptide consists of SEQ ID NO:16 or differs from SEQ ID NO:16 by substitution, deletion, and/or addition of about 1, 2, 3, 4, or 5 amino acids.
8. The therapeutic composition of claim 1 , wherein the DRS polypeptide is up to about 240 amino acids in length and comprises SEQ ID NO:16 or a sequence that is at least 95% identical to SEQ ID NO:16.
9. The therapeutic composition of claim 8 , wherein the DRS polypeptide is up to about 240 amino acids in length and comprises SEQ ID NO:16.
10. The therapeutic composition of claim 1 , wherein the DRS polypeptide comprises SEQ ID NO:16 or 14.